The growing armamentarium of potential radioisotopes and increased demand for radiopharmaceuticals (RPs)have catapulted their biomedical applications on a trajectory of higher growth in the modern healthcareestablishment. Nuclear medicine technology is now regarded as an essential tool for diagnosis, palliation,therapy, and theranostic applications. The associated radiation safety issues need to be emphasized in the formof adequate regulatory action to warrant their safe and effective use. The RPs attracts considerable attentionfrom both pharmaceutical and nuclear regulators due to their constituent pharmaceutical and radioactivecomponents. So, a critical examination of applications of RPs, the latest advances in their development, and theexisting regulatory guidelines for RPs have been carried out. This review presents a brief overview of RPs andrecent studies on their diagnostic, therapeutic, and theranostic applications. Comprehensive comparativeinformation on regulatory perspectives of RPs in major pharmaceutical jurisdictions such as the United States(US), the European Union (EU), and India reveals ambiguities and heterogeneity. The present studies discussthe importance of RPs in the current healthcare domain, their recent applications, and strive to intensify theconcern for an ambient and harmonized regulatory setup.
Volume 46, 2021
Continuous Article Publishing mode
Click here for Editorial Note on CAP Mode